Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib

Gefitinib and erlotinib are the first-line tyrosine kinase inhibitors (TKI) for advanced non-small-cell lung cancer. However, co-administration of either drug with proton pump inhibitors (PPI) or histamine-2 receptor antagonists (H2RA) may reduce TKI’s bioavailability. Therefore, we aimed to investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chia-Han, Shen, Mei-Chiou, Tsai, Ming-Ju, Chang, Jung-San, Huang, Yaw-Bin, Yang, Yi-Hsin, Hsieh, Kun-Pin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054789/
https://www.ncbi.nlm.nih.gov/pubmed/35488047
http://dx.doi.org/10.1038/s41598-022-10938-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054789/
https://www.ncbi.nlm.nih.gov/pubmed/35488047
http://dx.doi.org/10.1038/s41598-022-10938-x

Ejemplares similares